PPARA and Parkinson disease: Furthermore, additional experiments need to demonstrate if PPAR agonists provide protection in a regional-specific model of PD, such as the lentiviral-based delivery of α-synuclein (Lo et al., 2002), thus demonstrating the relevance of PPARs as a potential neuroprotective therapy.